We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Continuous Purification Technique Should Significantly Reduce Antibody Production Costs

By LabMedica International staff writers
Posted on 29 Mar 2015
Print article
Image: An Austrian Research Center of Industrial Biotechnology researcher is shown working with a laboratory scale continuous antibody purification reactor (Photo courtesy of the Austrian Research Center of Industrial Biotechnology).
Image: An Austrian Research Center of Industrial Biotechnology researcher is shown working with a laboratory scale continuous antibody purification reactor (Photo courtesy of the Austrian Research Center of Industrial Biotechnology).
An Austrian biotechnology firm has developed a method for the continuous purification of recombinant antibodies from cultures of clarified Chinese hamster ovary (CHO) cells that promises to significantly reduce the production costs of these important therapeutic and research materials.

Investigators at the Austrian Center of Industrial Biotechnology (Graz) replaced batch manufacture of protein A affinity chromatography-purified antibodies with a much simpler and cheaper continuous precipitation method. Currently about 80% of antibody production costs are due to the purification step.

The new precipitation process is based on a cheap mineral salt (CaCl2) and an organic solvent (ethanol). In this system purification of the antibodies depends on calcium-phosphate flocculation with subsequent cold ethanol precipitation in a tubular reactor that is a double-pipe heat exchanger operated in counter-current flow mode.

In a feasibility study that was published in the March 17, 2015, online edition of the Biotechnology Journal the investigators showed that the time from startup until attaining steady state conditions was reached in less than 15 minutes, and both reactors were operated for several hours at steady state without manual intervention, delivering antibody at a constant yield and purity. An overall yield of greater than 90%, with a host cell protein reduction from 42,777 to 9,000 parts per million and a DNA reduction from 359 to 7 parts per million, could be achieved for the antibody investigated. This system enabled cell culture supernatants with low or high antibody titer to be processed with constant reactor size and without changing any parameters or increasing precipitant consumption. Aggregate levels were below 1% under all conditions tested.

"Our method shows great potential as a new platform technology for the pharmaceutical industry," said senior author Dr. Alois Jungbauer, professor of biotechnology and head of bioprocess engineering at the Austrian Centre of Industrial Biotechnology.

Related Links:

Austrian Center of Industrial Biotechnology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.